Definitive Diagnostics is a pioneering biotechnology company utilizing a patented protein-based blood test to enhance the accuracy and affordability of cancer detection, with an initial focus on breast cancer diagnostics.

Mission and Innovation
The company addresses major unmet needs in cancer diagnostics by offering a minimally invasive alternative to confirmatory biopsies after positive mammograms, aiming to accelerate diagnosis, reduce anxiety, and eliminate unnecessary procedures.

Technology and Impact
Definitive Diagnostics’ proprietary, AI-enhanced protein biomarker technology delivers high sensitivity (up to 99%) and specificity (up to 97%) for early cancer detection, surpassing industry benchmarks and supporting broad clinical adoption. The company’s approach not only improves outcomes for patients but also provides substantial savings to payers and health systems by reducing wasteful follow-up tests and biopsies.

Broader Vision
Founded by recognized leaders in diagnostics and molecular biology, Definitive Diagnostics is committed to expanding its test platform to additional cancer types, building a pipeline of confirmatory and screening solutions that address critical gaps in care across the oncology landscape.